Inovio Pharmaceuticals, Inc. (INO) - NASDAQ
  • Mon, Mar. 14, 10:13 AM
    • Inovio Pharmaceuticals (INO -6%) acquires all the assets of Bioject Medical Technologies (OTC:BJCT), including its needle-free injection technology, for $5.5M in cash and stock. The transaction complements Inovio's needle-free skin surface electroporation technology under development for the potential administration its DNA vaccines.
    • Under the terms of the deal, Bioject will receive $4.5M in Inovio stock and $1.0M in cash.
    | Mon, Mar. 14, 10:13 AM | 4 Comments
  • May 27, 2014, 6:58 AM
    • VGX Animal Health, 90% owned by Inovio Pharmaceuticals (INO), sells its animal health assets to Seoul-based Plumbine Life Sciences (PLS). Included in the sale is an exclusive license with Inovio for animal applications of its growth-releasing hormone (GHRH) technology and animal DNA vaccines and a non-exclusive license to INO electroporation delivery systems.
    • VGX receives $2M cash in multiple payments, a 20% stake in PLS plus milestone payments and royalties on product sales.
    • Inovio retains the human applications of its GHRH technology.
    • On another note, INO announces that its DNA-based therapeutic mAb targeting Chikungunya (CHIKV) virus completely protected mice from a lethal CHIKV challenge in a preclinical study. There is currently no vaccine or therapuetic against this mosquito-borne disease. Much work remains, though, before the product is available for human use.
    | May 27, 2014, 6:58 AM | 4 Comments
Company Description
Inovio Pharmaceuticals, Inc. is revolutionizing the fight against cancer and infectious diseases. Its immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding... More
Sector: Healthcare
Industry: Biotechnology
Country: United States